Pluri Inc.

Medical Disclaimer: The information on WikiMD is provided as an information resource only, and is not to be used or relied on for any diagnostic or treatment purposes. This information should not be used as a substitute for professional diagnosis and treatment. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter this site.

Logo of Pluri Inc.

Pluri Inc. is a biotechnology company that specializes in the development of cell therapy products derived from placental cells. The company is headquartered in Haifa, Israel, and is known for its innovative approach to regenerative medicine and cell therapy.

History

Pluri Inc., originally known as Pluristem Therapeutics, was founded in 2001. The company was established with the goal of harnessing the potential of placental cells for therapeutic purposes. Over the years, Pluri Inc. has developed proprietary technology platforms that enable the expansion and differentiation of placental cells into various cell types for clinical applications.

Technology

Pluri Inc. utilizes a unique 3D cell expansion technology known as the PLX (PLacental eXpanded) platform. This technology allows for the large-scale production of allogeneic cell therapy products. The PLX platform is designed to produce cells that can be administered without the need for immunosuppression, making them suitable for a wide range of patients.

PLX Cells

PLX cells are mesenchymal-like adherent stromal cells derived from the placenta. These cells are expanded using Pluri Inc.'s proprietary 3D bioreactor system, which mimics the natural environment of the cells, enhancing their therapeutic potential. PLX cells have been investigated for their ability to secrete a range of therapeutic proteins in response to inflammation and tissue damage.

Clinical Applications

Pluri Inc. is focused on developing cell therapy products for a variety of medical conditions. Some of the key areas of research and development include:

Peripheral Artery Disease

PLX cells are being studied for their potential to treat peripheral artery disease (PAD), a condition characterized by reduced blood flow to the limbs. Clinical trials have shown that PLX cells can improve blood flow and promote tissue regeneration in patients with PAD.

Muscle Injury

The company is also exploring the use of PLX cells for the treatment of muscle injuries. Preclinical studies suggest that these cells can enhance muscle regeneration and reduce inflammation following injury.

Radiation Exposure

Pluri Inc. has conducted research on the use of PLX cells to mitigate the effects of acute radiation syndrome. The cells have shown promise in reducing mortality and improving recovery in animal models exposed to high levels of radiation.

Research and Development

Pluri Inc. collaborates with various academic and medical institutions to advance its research and development efforts. The company is committed to exploring new therapeutic applications for its PLX technology and expanding its pipeline of cell therapy products.

Related pages

• Biotechnology
• Regenerative medicine
• Stem cell therapy
• Cell culture